ADC Therapeutics SA — Form 6-K Summary
Business context and reporting period
ADC Therapeutics SA filed a Form 6-K as a foreign private issuer for June 2021. The filing is dated June 9, 2021 and identifies the company’s principal executive office in Epalinges, Switzerland. The filing references Exhibit 99.1, a press release dated June 9, 2021, but the press release text is not included in the provided filing content.
Financial and operating metrics
The provided filing text does not include revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, operating metrics, or other financial results.
Changes versus the prior comparable period
The filing text does not provide information permitting comparison with a prior period.
Guidance, outlook, risks, and unusual items
The filing text does not provide guidance, outlook, management commentary, risk disclosures, contingencies, or unusual items. Any such information may be contained in the referenced but unavailable Exhibit 99.1 press release.
Important facts to verify
- Obtain and review Exhibit 99.1, the June 9, 2021 press release.
- Verify whether the press release contains material financial, clinical, regulatory, financing, or business updates.
- Confirm any guidance, cash runway, liquidity, or risk information against the company’s latest Form 20-F and subsequent filings.